Search hospitals > Washington > Aberdeen

Providence Regional Cancer System-Aberdeen

Claim this profile
Aberdeen, Washington 98520
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
177 reported clinical trials
6 medical researchers
Photo of Providence Regional Cancer System-Aberdeen in AberdeenPhoto of Providence Regional Cancer System-Aberdeen in AberdeenPhoto of Providence Regional Cancer System-Aberdeen in Aberdeen

Summary

Providence Regional Cancer System-Aberdeen is a medical facility located in Aberdeen, Washington. This center is recognized for care of Cancer, Lung Cancer, Adenocarcinoma, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Providence Regional Cancer System-Aberdeen is involved with conducting 177 clinical trials across 395 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.

Area of expertise

1Cancer
Global Leader
Providence Regional Cancer System-Aberdeen has run 71 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Lung Cancer
Global Leader
Providence Regional Cancer System-Aberdeen has run 25 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage I

Top PIs

Clinical Trials running at Providence Regional Cancer System-Aberdeen

Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Lung Cancer
Pancreatic Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Pancreatic Carcinoma
Multiple Myeloma
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Providence Regional Cancer System-Aberdeen?
Providence Regional Cancer System-Aberdeen is a medical facility located in Aberdeen, Washington. This center is recognized for care of Cancer, Lung Cancer, Adenocarcinoma, Breast Cancer, Non-Small Cell Lung Cancer and other specialties. Providence Regional Cancer System-Aberdeen is involved with conducting 177 clinical trials across 395 conditions. There are 6 research doctors associated with this hospital, such as Alison K. Conlin, Charles W. Drescher, Nitya Alluri, and Krishna C. Alluri.